North-star perspectives for Actinium-225 production at commercial scale

December 21, 2018

Alpha Immuno Therapy (AIT) or Targeted Alpha Therapy (TAT) refers to the use of medicines conjugated with alpha particle emitting elements to target specific tissues. Advanced drug delivery technologies allow researchers to deliver molecules directly to cancer cells.

Actinium-225 and Bismuth-213 are used in AIT However, both of these isotopes have low production yields and their production currently doesn't match the scales of their consumption in medical processes. In numerical terms, it costs way much more per millicurie for long term sustainability of production.

This review presented by James Harvey from Northstar Medical Technologies LLC - and published in Current Radiopharmaceuticals - shares information about useful techniques which can be employed for making Actinium-225 more sustainable in the long term. Harvey summarizes the importance of new techniques required to produce larger quantities of Actinium and presents the information about the leading producers of Actinium. This is followed by details of established and experimental methods of Actinium production.
-end-
About Northstar Medical Technologies LLC

NorthStar Medical Radioisotopes, LLC is a privately held nuclear medicine technology company committed to providing reliable and environmentally friendly radioisotope supply solutions to meet patient needs and advance clinical research. Founded in 2006 and based in Beloit, Wisconsin, NorthStar is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC.

This article is Open Access. To obtain the article please visit http://www.eurekaselect.com/162155

Bentham Science Publishers

Related Actinium Articles from Brightsurf:

Story tips: Shuffling atoms, thinning forests, fusion assembly and nuclear medicine
ORNL Story Tips: Shuffling atoms, thinning forests, fusion assembly and nuclear medicine.

Prostate cancer: radiation therapy effective in patients with no further treatment options
Prostate cancer accounts for 26 percent of male cancer cases diagnosed in Germany.

New technique could optimize PSMA-targeted prostate cancer therapy
Researchers have discovered a new way to optimize results in treating patients with prostate cancer tumors while minimizing negative side effects.

Separation anxiety no more: A faster technique to purify elements
Researchers at Lawrence Berkeley National Laboratory have developed a new chemical separation method that is vastly more efficient than conventional processes, opening the door to faster discovery of new elements, easier nuclear fuel reprocessing, and, most tantalizing, a better way to attain actinium-225, a promising therapeutic isotope for cancer treatment.

Gilteritinib improved survival for patients with acute myeloid leukemia
Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy regimens, according to results from the ADMIRAL phase III clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.

Sea worms and jellyfish treat cancer and kill insects
Scientists of the Pacific Institute of Bioorganic Chemistry (PIBOC) of the Far Eastern Branch of the Russian Academy of Sciences (FEB RAS) and the Far Eastern Federal University (FEFU) found out marine invertebrates living in Troitsa Bay, the Sea of Japan, contain biologically active compounds with strong antitumor and antimicrobial properties, and also capable of killing insects.

North-star perspectives for Actinium-225 production at commercial scale
Resolution of both supply and cost issues allows clinical research to proceed through clinical trials and potentially produce one or more effective therapies for cancer or infectious diseases that could benefit the public.NorthStar Medical Technologies, LLC, has investigated several routes that could lead to commercial scale production of actinium-225.The outlook for future supplies of actinium-225 from multiple sources to support clinical needs is encouraging.

The production of Ac-225
This manuscript attempts to present an overview of availability sources of 225Ac and production methods by which additional supplies might be made available to the community of clinical researchers seeking their application in the treatment of human disease.

Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise
In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival.

Novel nuclear medicine approach shows promise for treating wide array of cancerous tumors
A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer--including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children.

Read More: Actinium News and Actinium Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.